JP2025510815A5 - - Google Patents
Info
- Publication number
- JP2025510815A5 JP2025510815A5 JP2024556630A JP2024556630A JP2025510815A5 JP 2025510815 A5 JP2025510815 A5 JP 2025510815A5 JP 2024556630 A JP2024556630 A JP 2024556630A JP 2024556630 A JP2024556630 A JP 2024556630A JP 2025510815 A5 JP2025510815 A5 JP 2025510815A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2204159.4A GB202204159D0 (en) | 2022-03-24 | 2022-03-24 | Antibodies |
| GB2204159.4 | 2022-03-24 | ||
| PCT/GB2023/050760 WO2023180767A1 (en) | 2022-03-24 | 2023-03-24 | Anti-par2 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025510815A JP2025510815A (ja) | 2025-04-15 |
| JP2025510815A5 true JP2025510815A5 (https=) | 2026-03-31 |
Family
ID=81449405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024556630A Pending JP2025510815A (ja) | 2022-03-24 | 2023-03-24 | 抗ｐａｒ２抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250313621A1 (https=) |
| EP (1) | EP4499694A1 (https=) |
| JP (1) | JP2025510815A (https=) |
| KR (1) | KR20240161970A (https=) |
| CN (1) | CN119137152A (https=) |
| AU (1) | AU2023238937A1 (https=) |
| CA (1) | CA3246035A1 (https=) |
| GB (1) | GB202204159D0 (https=) |
| IL (1) | IL315704A (https=) |
| WO (1) | WO2023180767A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024255639A1 (en) * | 2023-04-14 | 2025-10-02 | Triveni Bio, Inc. | Dual inhibitor trypsin antibodies and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2327382T3 (es) | 1999-07-20 | 2009-10-29 | Morphosys Ag | Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro. |
| US7888482B2 (en) * | 2006-02-10 | 2011-02-15 | Amgen Inc. | Antibodies that bind PAR-2 |
| JO3246B1 (ar) * | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
| MX2019010802A (es) | 2017-03-16 | 2019-10-30 | Medimmune Ltd | Anticuerpos anti-par2 y usos de los mismos. |
| SMT202500106T1 (it) * | 2020-08-18 | 2025-05-12 | Cephalon Llc | Anticorpi anti-par-2 e loro metodi d'uso |
-
2022
- 2022-03-24 GB GBGB2204159.4A patent/GB202204159D0/en not_active Ceased
-
2023
- 2023-03-24 US US18/850,322 patent/US20250313621A1/en active Pending
- 2023-03-24 CN CN202380035677.6A patent/CN119137152A/zh active Pending
- 2023-03-24 KR KR1020247034959A patent/KR20240161970A/ko active Pending
- 2023-03-24 WO PCT/GB2023/050760 patent/WO2023180767A1/en not_active Ceased
- 2023-03-24 EP EP23718801.6A patent/EP4499694A1/en active Pending
- 2023-03-24 JP JP2024556630A patent/JP2025510815A/ja active Pending
- 2023-03-24 IL IL315704A patent/IL315704A/en unknown
- 2023-03-24 CA CA3246035A patent/CA3246035A1/en active Pending
- 2023-03-24 AU AU2023238937A patent/AU2023238937A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI850203B (zh) | 抗體、可活化之抗體、雙特異性抗體、和雙特異性可活化之抗體、及其使用方法 | |
| JP5632744B2 (ja) | ヒト神経成長因子に対する高親和性ヒト抗体 | |
| FI3740504T3 (fi) | CD70-yhdistelmähoito | |
| JP2020536109A5 (https=) | ||
| CN115850521A (zh) | 靶向性治疗剂及其用途 | |
| AU2021221287B2 (en) | Engineered anti-IL-2 antibodies | |
| JP2018523686A5 (https=) | ||
| CA2792740A1 (en) | Antibodies with ph dependent antigen binding | |
| RU2011128332A (ru) | Антитело против siglec-15 | |
| JP2011502137A5 (https=) | ||
| WO2023174396A1 (zh) | 一种新型免疫调节剂的开发和应用 | |
| AU2016369307A1 (en) | Multi-specific antibody molecules having specificity for TNF-alpha, IL-17A and IL-17F | |
| JP2023155262A (ja) | プレクチン１結合抗体およびその使用 | |
| JP2021511024A5 (https=) | ||
| AU2021378793B2 (en) | Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer | |
| JP2025510815A5 (https=) | ||
| CA3207494A1 (en) | Hhla2 binding agents with novel activity | |
| JP2009529915A5 (https=) | ||
| US20140065154A1 (en) | Tlr3 binding agents | |
| JP2022534794A5 (https=) | ||
| CN114040776A (zh) | Tlr激动剂与抗ox40抗体或其抗原结合片段联合在制备治疗肿瘤的药物中的用途 | |
| CN109071659B (zh) | 人抗fgfr4抗体和索拉非尼的组合 | |
| TWI865617B (zh) | 抗原結合蛋白 | |
| JP2019535716A5 (https=) | ||
| JP2023527200A5 (https=) |